herpetrione: structure in first source
ID Source | ID |
---|---|
PubMed CID | 16037396 |
MeSH ID | M0586503 |
Synonym |
---|
3-hydroxy-2-[2-hydroxy-5-[3-(4-hydroxy-3-methoxy-phenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-3-methoxy-phenyl]-1-(4-hydroxy-3-methoxy-phenyl)propan-1-one |
herpetrione |
hpe , |
Herpetrione (HPE) is a new compound extracted from Herpetospermum caudigerum. It is proved to be a novel and potent antiviral agent.
Excerpt | Reference | Relevance |
---|---|---|
"Herpetrione (HPE), is a new compound extracted from Herpetospermum caudigerum, which is proved to be a novel and potent antiviral agent. " | ( Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension. Fu, SS; Guo, JJ; Han, J; Jin, SX; Jin, SY; Lv, JL; Yuan, HL; Yue, PF, 2013) | 2.08 |
Excerpt | Reference | Relevance |
---|---|---|
" However, due to poor water solubility, oral bioavailability of the drug was relatively low." | ( Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension. Fu, SS; Guo, JJ; Han, J; Jin, SX; Jin, SY; Lv, JL; Yuan, HL; Yue, PF, 2013) | 0.64 |
"In this study, a novel orodispersible film (ODF) containing drug nanoparticles was developed with the goal of transforming drug nanosuspensions into a solid dosage form and enhancing oral bioavailability of drugs with poor water solubility." | ( Development and characterization of an orodispersible film containing drug nanoparticles. Bai, JX; Dai, L; Han, J; Lv, QY; Shen, BD; Shen, CY; Xu, H; Yu, C; Yuan, HL; Yuan, XD, 2013) | 0.39 |
"The present study was designed to improve storage stability and oral bioavailability of Ganneng dropping pills (GNDP) by transforming lignans of Herpetospermum caudigerum (HL) composed of herpetrione (HPE) and herpetin (HPN) into nanosuspension (HL-NS), the main active ingredient of GNDP, HL-NS was prepared by high pressure homogenization and lyophilized to transform into solid nanoparticles (HL nanoparticles), and then the formulated HL nanoparticles were perfused into matrix to obtain NS-GNDP by melting method." | ( Improved stability and oral bioavailability of Ganneng dropping pills following transforming lignans of herpetospermum caudigerum into nanosuspensions. Cheng, L; Li, JJ; Qiu, L; Shen, CY; Shen, G; Xu, R; Yuan, HL; Zheng, J, 2018) | 0.67 |
"Nanotechnology has been a primary strategy to enhance oral bioavailability of poorly water soluble drugs." | ( Exploring the translocation behaviours Hang, L; Shen, B; Shen, C; Wu, W; Xue, Y; Yuan, H, 2023) | 0.91 |
Excerpt | Relevance | Reference |
---|---|---|
"In this study, a novel orodispersible film (ODF) containing drug nanoparticles was developed with the goal of transforming drug nanosuspensions into a solid dosage form and enhancing oral bioavailability of drugs with poor water solubility." | ( Development and characterization of an orodispersible film containing drug nanoparticles. Bai, JX; Dai, L; Han, J; Lv, QY; Shen, BD; Shen, CY; Xu, H; Yu, C; Yuan, HL; Yuan, XD, 2013) | 0.39 |
" The results demonstrated that uniformity of dosage units of NS-GNDP was acceptable according to the criteria of Chinese Pharmacopoeia 2015J." | ( Improved stability and oral bioavailability of Ganneng dropping pills following transforming lignans of herpetospermum caudigerum into nanosuspensions. Cheng, L; Li, JJ; Qiu, L; Shen, CY; Shen, G; Xu, R; Yuan, HL; Zheng, J, 2018) | 0.48 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (85.71) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |